This week, we will discuss the MENTOR trial, which pitted rituximab versus cyclosporine for membranous nephropathy

This week, we will discuss an RCT, a pediatric RCT, and a pediatric RCT in childhood nephrotic syndrome! A trial that asks a question of burning importance to the management of childhood nephrotic syndrome. Join us as we tackle PREDNOS.

Atrosentan makes a return visit to NephJC, but now it goes beyond changes in proteinuria and shows improved kidney outcomes. Is it enough to overcome the fluid complications?

This week, we will discuss a risk score which helps to prognosticate the most common glomerular disease. Not only is IgA most common - it is quite heterogeneous, which makes the problem of who should get treated quite difficult.

They always said not to correct hypernatremia faster than 0.5 mmol/L/hour but what do they know and who are they anyways? New data questions this ancient dogma.